Cancer Commentary by Prof. Cornelis Melief published in MedNous, October 2016 01 Nov 2016 Previous ISA Pharmaceuticals’ CSO Prof. Cornelis Melief to Present at CRI-CIMT-EATI-AACR Meeting in New York City Next ISA Pharmaceuticals participates in newly-launched Tumor Neoantigen Selection Alliance (TESLA)
